anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Apparatus for use in sunbathing comprises a screen formed of a sheet of thermoplastic or fiber material which is transparent to the safe UV-A wavelengths of solar radiation and the visible light range between 400-450 nm but which contains uniformly distributed therethrough a first agent which absorbs at least 80% of the UV-B radiation in the 310-320 nm range and all radiation below 310 nm and a second agent and third agent which prevent transmission therethrough of some radiations above 450 nm wavelength, i.e. visible light and infra-red. The second agent may be an absorbing dye or pigment. The third agent may be finely divided carbon or ground glass. The screen may be mounted on a frame or fabricated into clothing so as to shield the sunbather from the acutely and chronically harmful wavelengths of radiation, to prevent unpleasant overheating, and to provide subdued lighting. The relatively small amount of UV-B transmitted through the material stimulates the production of new melanin in a sunbather, and this melanin will be later available for tanning by UV-A radiation.
Project Summary/Abstract Deficits in working memory (WM) comprise a core, transdiagnostic feature of childhood and adolescent psychopathology. WM is one of the strongest predictors of clinical and functional outcomes, yet there remains a dearth of treatments available for WM deficits. WM was historically conceptualized as solely localized to the dorsolateral prefrontal cortex, while modern technology has established the broader role of the prefrontal cortex (PFC) and posterior parietal cortex (PPC). There is evidence to suggest that PPC receives direct input from PFC, although other evidence suggests the PPC encodes incoming stimuli and feeds forward to the PFC for the initiation of control functions. I have previously found that frontoparietal theta/gamma oscillations, particularly theta-gamma coupling, is a neural mechanism underlying WM processes. Novel approaches to non-invasive brain stimulation, such as intermittent theta burst stimulation (iTBS) can now modulate these distinct oscillatory dynamics and subsequently examine possible causal or temporal relationships. This award would build on my preliminary findings and transition my career from a clinician to an independent researcher. The objective of this Patient-Oriented Research Career Development Award (K23) is to provide the necessary training for me to obtain my career goal of utilizing a multimodal neuroscientific approach to measure and modulate the neural dynamics underlying neurocognitive deficits in childhood and adolescent psychopathology. In line with NIMH priorities, the training plan proposed will build upon my clinical neuropsychology and clinical research foundation to provide comprehensive training and mentorship in two core areas: 1) Neuromodulation and 2) Computational Neuroscience. In a 2x2 factorial double-blind design, the researchers will randomize a sample of 40 adolescents (12-18 years) with WM deficits to iTBS at the left DLPFC or inferior parietal lobule (IPL). Participants will complete an active iTBS session and a sham iTBS session. The primary outcome will be theta-gamma coupling during WM demands, as measured via electroencephalography during a spatial WM task immediately before and after iTBS. Aim 1 will examine the effect of iTBS to the PPC on the encoding stage of WM, while Aim 2 will examine the effect of iTBS to the PFC on the maintenance stage of WM. Aim 3 will utilize computational neural modeling to identify the neocortical circuitry underlying oscillatory modulation. My central hypothesis is that the PFC and PPC regions have complimentary roles in executing WM processes. Further, iTBS can modulate theta-gamma coupling in these regions to improve behavioral performance. The researchers will establish a framework for modulating oscillatory dynamics in child psychiatry and set the stage for my first R01 on WM-related frontoparietal oscillatory dynamics and optimal treatment parameters for adolescent WM deficits. This will provide the foundation required to dedicate my career to measuring and modulating oscillatory abnormalities in child psychiatry.
This arm will receive standard supportive care according to guidelines for COVID-19. This is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
Small gauge pars plana vitrectomy (PPV) with membrane peeling is used to successfully treat macular epiretinal membranes (ERMs) with a postoperative improvement of visual acuity in the majority of cases. Traditionally, the treatment of ERMs has been performed purely by peeling the membrane mechanically and then waiting for the intraretinal edema to resolve spontaneously. In the last few years, some publications raised the possibility that triamcinolone acetonide (TA),given as an intravitreal injection at the end of surgery, can accelerate the resorption of intraretinal edema and hasten the improvement in the visual acuity. It has been shown to facilitate fluid absorption by both stimulating endogenous adenosine signaling in Muller cells and by down regulating vascular endothelial growth factor production. Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant activity 30 times that of cortisol and 6 times that of triamcinolone. As the postoperative cystoid macular edema usually peaks 4 to 6 weeks after surgery the difference in the half life can be significant and explained the results in past publications. While the use of intravitreal TA as an adjuvant to PPV with membrane peel showed conflicting results. Only few publications demonstrated the effectiveness of Ozurdex in the treatment of macular edema in a vitrectomized eye, after ERM removal.So, this study aim to investigate the efficacy of Ozurdex implant after PPV in epiretinal membrane eyes.
A novel composite for internal application within wounds, incisions, and the like, for the prevention of biofilm growth therein is provided. Such a composite includes an antibiotic introduced within a sponge-like chitosan delivery product with electrically conductive nanomaterials present. Such a delivery product is also lyophilized subsequent to nanomaterial introduction but prior to antibiotic inclusion. The inventive lyophilized composite permits delivery of needed antibiotics internally within a patient with the simultaneous exposure to a sufficiently strong electrical current to permit a synergistic effect of increased antibiotic efficacy. In such a manner, relatively low amounts of antibiotic may be utilized to reduce the propensity of biofilm formation and/or growth within a wound or incision, or on the surface of an implant. Additionally, the lyophilized chitosan/nanomaterial composite allows for a maximum amount of antibiotic to be introduced with maximum elution therefrom as well. Lastly, the chitosan degrades over time within the subject's body, thereby avoiding any further invasive removal procedures. The method of such a manner of delivering improved antibiotic efficacy for biofilm prevention is encompassed within this invention as well.
FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical composition comprises cyclosporine A as an active substance, surface-active substance and hydrophilic phase. Surface-active substance acts as hydrophilic-lipophilic balance with value at least 10 and represents product of reaction of natural or hydrogenated vegetable oil and ethylene glycol. Hydrophilic phase contains polyethylene glycol and at least one lower alkanol. Alkanol represents ethanol or propylene glycol. Each of indicated lower alkanols is taken in the amount less 12% with respect to the total mass of composition. Composition is adapted for filling with gelatin capsule with solid film. Compositions containing cyclosporine have small volume, they are stable in storage into capsules that enhances the ease of their usage by patients. Capsules are not friable. EFFECT: improved and valuable pharmaceutical properties of capsule. 17 cl, 4 ex
This cross-sectional study investigated health-related behaviours in Korean cancer survivors by time after cancer diagnosis. The data of 50,532 subjects (aged 40 to 79 years) who participated in the 2007-2019 Korean National Health and Nutrition Examination Surveys (KNHANES) were subjected to analysis. Health-related behaviours included obesity, current smoking, frequent drinking, influenza vaccination, health screening, and cancer screening. The odds for these behaviours were estimated by multivariate logistic regression models with adjustment for potential covariates. Approximately 5% of subjects were cancer survivors, and among these three-fifths were long-term (≥5 years) survivors. Cancer survivors had healthier behaviours than non-survivors for almost all behaviours. However, these trends were attenuated in long-term survivors. In conclusion, healthy behaviour should be emphasised for long-term cancer survivors. Key Words: Cancer survivors, Cross-sectional studies, Health-related behaviours.
INTRODUCTION: According to the PRISMA guidelines, this systematic review of randomized controlled trials examined whether Panax ginseng supplementation reduces resistance to exercise-induced muscle damage (EIMD).
EVIDENCE ACQUISITION: Web of Science, SPORTDiscus and Medline databases were searched from the 16th of December 2021 to the 18th of February 2022. Inclusion criteria were studies in humans consuming Panax ginseng that employed resistance training as the damaging muscle protocol and measured markers implicated in the etiology of EIMD (muscle damage, muscle function and muscle soreness). The PEDro risk of bias assessment tool was used to appraise the studies critically.
EVIDENCE SYNTHESIS: Conflicting evidence was evident in markers of muscle damage, muscle function and muscle soreness. The quality assessment suggested that all studies had some level of bias.
CONCLUSIONS: From 180, six studies were included in the systematic review. The main findings suggest that Panax ginseng does not attenuate markers of EIMD following resistance training. However, research is still preliminary. Adequately powered sample sizes and well-controlled studies are warranted to clarify Panax ginseng's efficacy.
Participants will receive AZD0486 monotherapy as SC injection. Participants will receive acalabrutinib tablet orally twice daily.
Persons with Parkinson's disease (PD) often experience non-motor symptoms such as cognitive dysfunction and sleep problems. These symptoms can be more disabling than the motor symptoms of PD. Medications are often not effective for treating these non-motor symptoms or can have unwanted side effects. Non- medication treatments such as exercise are known to improve the motor symptoms of PD, but the effect of exercise on cognition and sleep has not been fully explored. This study investigates the impact of 16 weeks of supervised exercise, 3 times per week, compared to no-exercise over the same duration, on cognition and sleep dysfunction. Participants will be evaluated with cognitive tests and sleep studies before and after 16-weeks to determine the impact of this exercise intervention. The goal of this research is to identify an intervention that will improve cognition and sleep in persons with PD.
The standard post-surgical protocol applied in our clinic will be applied to Group 2. The clinical evaluation will be made on the 15th, 45th and 90th days; functional measurements will be taken. The follow-up period was determined as 3 months.
In advanced stages of PD, motor symptoms and dyskinesia are effectively treated by deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) . Traditionally, in this procedure, stimulation is set to a constant frequency electrical stimulation with the physician programming the parameters of stimulation frequency, pulse width and amplitude, and stimulated patients' brain nuclei with single frequency, single pulse width and single amplitude of the electric stimulation. Indeed, high frequency stimulation (HFS) of the STN provides consistent, long-term improvement of the cardinal signs of PD . However, the treatment effects of HFS on the axial symptoms of PD, specifically FOG can be poor often causing further impairment. While this can be alleviated by using relatively low frequency stimulation (LFS) , major concerns in the clinical application of LFS exist in regards to its duration of therapeutic benefit. Previous studies have shown that LFS of the STN improves the axial motor signs in some PD patients, but a loss of therapeutic efficacy is seen in the short term. Thereafter, patients may present increased tremor, rigidity and bradykinesia, which is often intolerable outweighing the initial benefits of LFS therapy for FOG. As such, a suitable treatment strategy for FOG remains to be established.

Based on previous findings on the relationships between stimulation frequency and movement rhythm regulation in the human body, The National Engineering Laboratory for Neuromodulation, Tsinghua University, proposes a method of variable frequency stimulation (VFS) for aiding movement.
The Centers for Medicare & Medicaid Services (CMS) introduced the Severe Sepsis/Septic Shock Management Bundle (SEP-1) as a pay-for-reporting measure in 2015 and is now planning to make it a pay-for-performance measure by incorporating it into the Hospital Value-Based Purchasing Program. This joint IDSA/ACEP/PIDS/SHEA/SHM/SIPD position paper highlights concerns with this change. Multiple studies indicate that SEP-1 implementation was associated with increased broad-spectrum antibiotic use, lactate measurements, and aggressive fluid resuscitation for patients with suspected sepsis but not with decreased mortality rates. Increased focus on SEP-1 risks further diverting attention and resources from more effective measures and comprehensive sepsis care. We recommend retiring SEP-1 rather than using it in a payment model and shifting instead to new sepsis metrics that focus on patient outcomes. CMS is developing a community-onset sepsis 30-day mortality electronic clinical quality measure (eCQM) that is an important step in this direction. The eCQM preliminarily identifies sepsis using systemic inflammatory response syndrome (SIRS) criteria, antibiotic administrations or diagnosis codes for infection or sepsis, and clinical indicators of acute organ dysfunction. We support the eCQM but recommend removing SIRS criteria and diagnosis codes to streamline implementation, decrease variability between hospitals, maintain vigilance for patients with sepsis but without SIRS, and avoid promoting antibiotic use in uninfected patients with SIRS. We further advocate for CMS to harmonize the eCQM with the Centers for Disease Control and Prevention's (CDC) Adult Sepsis Event surveillance metric to promote unity in federal measures, decrease reporting burden for hospitals, and facilitate shared prevention initiatives. These steps will result in a more robust measure that will encourage hospitals to pay more attention to the full breadth of sepsis care, stimulate new innovations in diagnosis and treatment, and ultimately bring us closer to our shared goal of improving outcomes for patients.
The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
Acute disseminated encephalomyelitis (ADEM) is one characteristic manifestation of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). A previously healthy man presented with retro-orbital headache and urinary retention 14 days after Tdap vaccination. Brain and spine MRI suggested a CNS demyelinating process. Despite treatment with IV steroids, he deteriorated, manifesting hemiparesis and later impaired consciousness, requiring intubation. A repeat brain MRI demonstrated new bilateral supratentorial lesions associated with venous sinus thrombosis, hemorrhage, and midline shift. Anti-MOG antibody was present at a high titer. CSF IL-6 protein was >2,000 times above the upper limits of normal. He improved after plasma exchange, then began monthly treatment alone with anti-IL-6 receptor antibody, tocilizumab, and has remained stable. This case highlights how adult-onset MOGAD, like childhood ADEM, can rapidly become life-threatening. The markedly elevated CSF IL-6 observed here supports consideration for evaluating CSF cytokines more broadly in patients with acute MOGAD.
Embodiments provide devices, systems and methods for the transdermal delivery of chelated compounds. One embodiment provides a method for the iontophoretic transdermal delivery of a chelated iron complex for the treatment of anemia. A first patch comprising an active electrode and a chelated iron complex is applied to the skin; a second patch containing an electrode is also applied. An electrical current is then delivered to the skin from the active electrode. The chelated complex is transported across the skin via electromotive force from the current, with the iron being substantially chromogenically unreactive with the skin during transport so that there is little or no tattooing of the skin due to the formation of insoluble oxidative products.; The complex is then dissociated to release the iron where it may be bound by transferrin or ferritin for storage or metabolic use such as heme synthesis.
ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.
Introduction: Systemic microvascular reactivity (MR) is an essential component of cardiovascular physiology, being studied through non-invasive techniques in readily accessible body regions, such as the skin surface. Heart transplant (HT) is a treatment considered to selected patients, with advanced heart failure. The main cause of long-term mortality after HT is graft vascular disease (GVD), a condition which starts with endothelial dysfunction. To know the evolution of systemic MR in patients subjected to HT can help to find prognostic factors. Objective: The present study aims to perform the prospective evaluation of systemic MR in adult patients, before and two years after HT, at a quaternary hospital, correlating the findings with clinical variables. Methods: Systemic MR will be evaluated in the skin of the forearm using laser speckle contrast imaging with acetylcholine (ACh) iontophoresis, followed by postocclusive reactive hyperemia (PORH), before and after HT. Measurements will be correlated to patient clinical profile, hemodynamic and echocardiographic data. Expected results: The evolution of systemic MR may aid in the comprehension of cardiovascular physiology in HT patients, and possibly suggest the non-invasive evaluation of skin microcirculation as an ancillary tool in the clinical evaluation of these patients.
Depletion of veins for dialysis access is a challenging life threatening situation for patients in need of haemodialysis. The utilisation of intracardiac catheter is a rare procedure with scarce reported experience. We describe the case of a 68-year-old male that contributes to the limited knowledge of performing a life-saving intracardiac catheter placement for emergency haemodialysis in a patient without immediate alternative renal replacement therapy available. We also retrospectively analyse the experience reported so far and summarise complications and outcomes. In our case, the patient was able to pursue haemodialysis after intracardiac catheter placement without any complications. Two weeks later, the patient successfully received a kidney transplant from a deceased donor and has a serum creatinine of 1.7 mg/dL after 2 years of follow-up. There are only four reported cases of kidney transplantation after the procedure, including our own. Intracardiac catheter is an emerging option that could be considered in certain patients as the last resort. Further investigation with regards to patient candidacy and procedure security are necessary.
FIELD: microbiology. SUBSTANCE: strain Brucella ovis И-107 is isolated from ram testicles. Strain shows stable R-form, nonagglutinable and nonagglutinogenic since agglutination reactions with polyvalent brucellosis and monospecific sera (antiabortus, antimelitensis) are negative. Animal infection with this strain does not cause the formation of S-antibodies. Strain Brucella ovis И-107 is deposited in Collection of living culture in brucellosis laboratory НИИЭМ named after N.F.Gamaleya at N 792. Antigenic properties: at rabbit immunization strain causes the formation of specific R-antibodies. Mean titer of antibodies in ИФА is 1:1638400 ± 126300, in РИД is 1: 16 + 8.3. R-antigen is used for preparing R-brucellosis erythrocyte diagnosticum titers of which are in the range from 1:800 to 1:3200. EFFECT: enhanced quality of strain.
PURPOSE:A cosmetic, obtained by incorporating dried powder of mung beans with other components, capable of exhibiting skin conditioning and beautifying action, and expectable vitamin A effect due to much carotene contained therein, and useful for fundamental cosmetic, e.g. toilet water or makeup cream, and soap, etc. CONSTITUTION:A cosmetic containing mung beans as the so-called natural plant powder with other components. The mung beans belong to beans, and are used as bean sprouts or a processing raw material for fen-tiao. The components in 100g are shown in the table, and carotene is contained, giving high vitamin A effect. The content of vitamin C is known to be high among the beans. The mung beans are usually treated as follows: The epidermis is peeled to give dried powder, or the beans are directly pulverized without peeling the epidermis. The above-mentioned powder is optimally particles having <=1/14mm. particle diameter. EFFECT:The effect is regarded as the action of protein and an enzyme, and the beautifying effect is further exhibited by fixing the cosmetic on the skin for a certain length of time.
The invention relates to the use of a medicament with a mixture of substances and the use of a mixture of substances on the basis of active agents from the hypericum plant (St. John's wort) to produce a medicament. Extracts from St John's wort have long been used in medicine, but for a long time solely to treat psychogenic disorders and insomnia. Such extracts contain small quantities of polycyclic diones (hypericin, pseudohypericin and/or salts thereof). An anti-viral and especially anti-retroviral effect of hypericin and pseudohypercin in highly pure form has recently been observed. However, the administration of such preparations has considerable side-effects, making them useless for therapeutic use. According to the invention, the active agent hypericin is dispensed not in highly pure form, but mixed with known components of the plant extract. Here, the concentration of hypericin/pseudohypericin is between 0.05 and 50 %. This provides good antiretroviral action while largely avoiding the undesired side-effects.
Neostigmine methylsulfate, a cholinesterase inhibitor, is (m-hydroxyphenyl) trimethylammonium methylsulfate dimethylcarbamate. The structural formula is: 

Neostigmine methylsulfate is a white crystalline powder and is very soluble in water and soluble in alcohol. Neostigmine methylsulfate injection USP, is a sterile, nonpyrogenic solution intended for intravenous use. 

Each mL of the 0.5 mg/mL strength contains neostigmine methylsulfate 0.5 mg, phenol 4.5 mg (used as preservative) and sodium acetate trihydrate 0.2 mg, in water for injection. The pH is adjusted, when necessary, with acetic acid/sodium hydroxide to achieve a value of 5.

Each mL of the 1 mg/mL strength contains neostigmine methylsulfate 1 mg, phenol 4.5 mg (used as preservative), and sodium acetate trihydrate 0.2 mg, in water for injection. The pH is adjusted, when necessary, with acetic acid/sodium hydroxide to achieve a value of 5.5.